Table 7.
Univariate Cox regression for tamoxifen-treated in estrogen receptor-positive breast carcinoma patients, N = 72.
| Factor base model | Disease-free survival |
Overall survival |
||||
|---|---|---|---|---|---|---|
| HR | CI 95% | P-value | HR | CI 95% | P-value | |
| Histological grade | 0.915-4.530 | 3.969 | 1.104-14.261 | 0.035 | ||
| Grade I | 20.34 | 0.081 | 0.715-14.328 | 0.128 | ||
| Grade II and III | 20.16 | 0.149 | ||||
| T stage | 1.63 | 0.816-3.270 | 0.166 | 1.835 | 0.720-4.672 | 0.203 |
| T1 and T2 | ||||||
| T3 and T4 | ||||||
| N stage | 2.63 | 1.355-5.128 | 0.004 | 2.132 | 0.850-5.287 | 0.103 |
| N0 and N1 | ||||||
| N0 and N1 | ||||||
| Extracapsular nodal extension | 2.17 | 1.20-4.06 | 0.012 | 2.002 | 0.76-5.274 | 0.160 |
| Absent | ||||||
| Present | ||||||
| Ductal carcinoma in situ histology | 1.01 | 0.395-2.620 | 0.973 | 1.840 | 0.609-5.557 | 0.280 |
| Comedo | ||||||
| Non-Comedo | ||||||
| Absent of nipple involvement | 1.41 | 0.585-3.434 | 0.44 | 1.099 | 0.317-2.810 | 0.881 |
| Lymphatic invasion | 1.78 | 0.742-4.296 | 0.196 | 1.828 | 0.531-6.268 | 0.339 |
| Perineural invasion | 2.32 | 1.99-4.499 | 0.013 | 0.787 | 0.310-1.999 | 0.614 |
| Absent | ||||||
| Present | ||||||
| PR status | 1.15 | 0.585-2.283 | 0.677 | 2.466 | 0.997-6.102 | 0.051 |
| Positive | ||||||
| Negative | ||||||
| HER2 status | 1.14 | 0.519-2.52 | 0.739 | 1.223 | 0.403-3.706 | 0.723 |
| Positive | ||||||
| Negative | ||||||
| Nicastrin expression | 4.336 | 2.027-9.275 | < 0.001 | 3.4 | 1.222-9.545 | 0.019 |
| Notch4 expression | 1.86 | 0.733-4.763 | 0.191 | 3.122 | 1.521-6.409 | 0.002 |
| Hes1 expression | 1.98 | 0.987-3.972 | 0.054 | 1.217 | 0.488-3.032 | 0.674 |
HR, Hazard ratio; HER2, Human epidermal growth factor receptor 2; Hes1, hairy enhancer of split, PR, progesterone receptor.